Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1378-1382, 2004. First published May 20, 2004; 10.1373/clinchem.2004.031799
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
clinchem.2004.031799v1
50/8/1378    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palomer, X.
Right arrow Articles by Blanco-Vaca, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palomer, X.
Right arrow Articles by Blanco-Vaca, F.
Related Collections
Right arrow Clinical Immunology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2004;50:1378-1382.)
© 2004 American Association for Clinical Chemistry, Inc.

Endocrinology and Metabolism

Evaluation of Two Nonisotopic Immunoassays for Determination of Glutamic Acid Decarboxylase and Tyrosine Phosphatase Autoantibodies in Serum

Xavier Palomer1,2, Dídac Mauricio2,4, José Rodríguez-Espinosa3, Edgar Zapico3, Carme Mayoral3, Francesc González-Sastre3,5, Alberto de Leiva2,5 and Francisco Blanco-Vaca1,3,a

1 Institut de Recerca, 2 Serveis d’Endocrinologia, and 3 Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 4 Hospital de Sabadell, Institut Universitari Parc Taulí, Sabadell, Spain. 5 Universitat Autònoma de Barcelona, Barcelona, Spain.

aAddress correspondence to this author at: Hospital de la Santa Creu i Sant Pau, Servei de Bioquímica, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Fax 34-93-2919196; e-mail fblancova{at}hsp.santpau.es.

Background: Autoantibodies for the 65-kDa form of glutamic acid decarboxylase (GAD65) and protein tyrosine phosphatase-like protein (IA-2) are measured for risk prediction and diagnosis of autoimmune diabetes mellitus. There is a lack of adequate nonisotopic alternatives to the most widely used method for both autoantibodies, which is a radiobinding assay (RBA).

Methods: We compared two commercially available immunoassays, an ELISA and a time-resolved immunofluorometric assay (TR-IFMA), with RBA.

Results: We found excellent agreement between the RBA and ELISA for measurement of GAD65 autoantibodies (GADAs); they showed comparable analytical precision in the cutoff range and achieved similar diagnostic specificity. The ELISA identified more GADA-positive individuals among patients with new-onset type 1 diabetes than did the RBA [89% (95% confidence interval, 78–95%), vs 71% (58–82%); P <0.03]. For IA-2 autoantibodies (IA-2As), only the TR-IFMA achieved analytical performance and diagnostic accuracy comparable to that of the RBA. These results with the GADA ELISA and IA-2A TR-IFMA were consistent with those obtained blindly in the Diabetes Antibody Standardization Program 2003. The performance of the GADA TR-IFMA and IA-2A ELISA was unsatisfactory, and these tests were not subjected to clinical evaluation.

Conclusions: The GADA ELISA and IA-2A TR-IFMA behave comparably with RBA and are thus suitable for use in the clinical laboratory.




The following articles in journals at HighWire Press have cited this article:


Home page
 Diabetes CareHome page
A. de Leiva, D. Mauricio, and R. Corcoy
Diabetes-Related Autoantibodies and Gestational Diabetes
Diabetes Care, July 1, 2007; 30(Supplement_2): S127 - S133.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.